Datapoint: Novo Scores Cardiovascular Expansion for Wegovy

The FDA signed off on a key label expansion for Novo Nordisk’s much-discussed weight loss drug Wegovy (semaglutide). The glucagon-like peptide-1 (GLP-1) receptor agonist is now approved to reduce the risk of cardiovascular death, heart attack and stroke in obese or overweight adult patients with cardiovascular disease. Trial data shows Wegovy reduced the risk of major adverse cardiovascular events by 20% compared to a placebo. For the treatment of obesity, Wegovy currently holds covered or better status for 53% of all insured lives. Just 11% have preferred access without any utilization management restrictions, while 45% have no covered access to the drug.

SOURCE: MMIT Analytics, as of 3/13/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 11

Datapoint: Amylyx Pulls ALS Drug Off the Market

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 10

Datapoint: FDA Grants J&J’s Carvykti Earlier, Expanded Use in Multiple Myeloma

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 9

Datapoint: GA Medicaid Expansion Could Bring Coverage to 300,000 People

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today